FGF21 is thought to reduce progression of NAFLD, and positive results have already been demonstrated in a small phase II trial of the PEGylated FGF21 analog Pegbelfermin [161]. This evidence concerns the gene FGF21 and metabolic dysfunction-associated steatotic liver disease.